ResolutionRx announces research & development financing agreement with Radium Capital
New York, New York
|
February 10, 2023 07:56 AM Eastern Standard Time
ResolutionRx Director Arnold Lippa joins Natalie Stoberman from the Proactive studio to discuss its recent letter of intent for financing with Radium Capital.
ResolutionRx Ltd is a wholly owned subsidiary of RespireRx Pharmaceuticals. ResolutionRx was formed in Australia on Jan. 11, 2023 by RespireRx as an unlisted public company.
RespireRx intends to contribute, sub-license, assign or otherwise make available to ResolutionRx, its cannabinoid drug development program subject to certain liabilities.
ResolutionRx would then engage in the R&D associated with that program, initially for the development of a new formulation of dronabinol for use in a Phase 3 clinical trial and the filing of regulatory approval for the treatment of obstructive sleep apnea.
Contact Details
Proactive United States
+1 347-449-0879
